216 related articles for article (PubMed ID: 33849091)
1. The effectiveness of EVOSKIN®Palm and sole moisturizing cream in treating capecitabine-associated hand-foot syndrome: a randomized double-blind clinical trial.
Lu W; Huang Z; Chen S; Lv H; Chen X; Lei J; Ke C; Hong C; Wei Y; Su R; Chen R; Sun Z; Yang P; Tan X; Liu H
Ann Palliat Med; 2021 Mar; 10(3):3009-3017. PubMed ID: 33849091
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of oral administration of cystine and theanine in colorectal cancer patients undergoing capecitabine-based adjuvant chemotherapy after surgery: a multi-institutional, randomized, double-blinded, placebo-controlled, phase II trial (JORTC-CAM03).
Hamaguchi R; Tsuchiya T; Miyata G; Sato T; Takahashi K; Miura K; Oshio H; Ohori H; Ariyoshi K; Oyamada S; Iwase S
Support Care Cancer; 2020 Aug; 28(8):3649-3657. PubMed ID: 31811480
[TBL] [Abstract][Full Text] [Related]
3. Study protocol of a single-arm phase 2 study evaluating the preventive effect of topical hydrocortisone for capecitabine-induced hand-foot syndrome in colorectal cancer patients receiving adjuvant chemotherapy with capecitabine plus oxaliplatin (T-CRACC study).
Iimura Y; Furukawa N; Ishibashi M; Ahiko Y; Tanabe T; Aikou S; Shida D; Nojima M; Kuroda S; Boku N
BMC Gastroenterol; 2022 Jul; 22(1):341. PubMed ID: 35836104
[TBL] [Abstract][Full Text] [Related]
4. Preplanned safety analysis of the JFMC37-0801 trial: a randomized phase III study of six months versus twelve months of capecitabine as adjuvant chemotherapy for stage III colon cancer.
Suto T; Ishiguro M; Hamada C; Kunieda K; Masuko H; Kondo K; Ishida H; Nishimura G; Sasaki K; Morita T; Hazama S; Maeda K; Mishima H; Ike H; Sadahiro S; Sugihara K; Okajima M; Saji S; Sakamoto J; Tomita N
Int J Clin Oncol; 2017 Jun; 22(3):494-504. PubMed ID: 28078540
[TBL] [Abstract][Full Text] [Related]
5. Predictors of Hand-Foot Syndrome and Pyridoxine for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized Clinical Trial.
Yap YS; Kwok LL; Syn N; Chay WY; Chia JWK; Tham CK; Wong NS; Lo SK; Dent RA; Tan S; Mok ZY; Koh KX; Toh HC; Koo WH; Loh M; Ng RCH; Choo SP; Soong RCT
JAMA Oncol; 2017 Nov; 3(11):1538-1545. PubMed ID: 28715540
[TBL] [Abstract][Full Text] [Related]
6. Randomized double-blind, placebo-controlled study of topical diclofenac in the prevention of hand-foot syndrome in patients receiving capecitabine (the D-TORCH study).
Santhosh A; Kumar A; Pramanik R; Gogia A; Prasad CP; Gupta I; Gupta N; Cheung WY; Pandey RM; Sharma A; Batra A
Trials; 2022 May; 23(1):420. PubMed ID: 35590388
[TBL] [Abstract][Full Text] [Related]
7. Effect of Extra-Virgin Olive Oil on Hand Foot Syndrome and hs-CRP in Patients Receiving Capecitabine: A Randomized Trial.
Andayani YD; Saleh MI; Sudoyo AW; Ali Z; Legiran L; Partan RU; Yuristo E; Lubis FZ
Acta Med Indones; 2023 Oct; 55(4):396-402. PubMed ID: 38213043
[TBL] [Abstract][Full Text] [Related]
8. The effect of TJ-28 (Eppikajutsuto) on the prevention of hand-foot syndrome using Capecitabine for colorectal cancer: The Yokohama Clinical Oncology Group Study (YCOG1102).
Watanabe K; Ishibe A; Watanabe J; Ota M; Fujii S; Ichikawa Y; Oba MS; Endo I
Indian J Gastroenterol; 2020 Apr; 39(2):204-210. PubMed ID: 32406009
[TBL] [Abstract][Full Text] [Related]
9. The effect of COX-2 inhibitor on capecitabine-induced hand-foot syndrome in patients with stage II/III colorectal cancer: a phase II randomized prospective study.
Zhang RX; Wu XJ; Lu SX; Pan ZZ; Wan DS; Chen G
J Cancer Res Clin Oncol; 2011 Jun; 137(6):953-7. PubMed ID: 21113620
[TBL] [Abstract][Full Text] [Related]
10. Prophylactic strategies for hand-foot syndrome/skin reaction associated with systemic cancer treatment: a meta-analysis of randomized controlled trials.
Pandy JGP; Franco PIG; Li RK
Support Care Cancer; 2022 Nov; 30(11):8655-8666. PubMed ID: 35655045
[TBL] [Abstract][Full Text] [Related]
11. Mapisal Versus Urea Cream as Prophylaxis for Capecitabine-Associated Hand-Foot Syndrome: A Randomized Phase III Trial of the AIO Quality of Life Working Group.
Hofheinz RD; Gencer D; Schulz H; Stahl M; Hegewisch-Becker S; Loeffler LM; Kronawitter U; Bolz G; Potenberg J; Tauchert F; Al-Batran SE; Schneeweiss A
J Clin Oncol; 2015 Aug; 33(22):2444-9. PubMed ID: 26124485
[TBL] [Abstract][Full Text] [Related]
12. Topical Diclofenac for Prevention of Capecitabine-Associated Hand-Foot Syndrome: A Double-Blind Randomized Controlled Trial.
Santhosh A; Sharma A; Bakhshi S; Kumar A; Sharma V; Malik PS; Pramanik R; Gogia A; Prasad CP; Sehgal T; Gund S; Dev A; Cheung WY; Pandey RM; Kumar S; Gupta I; Batra A;
J Clin Oncol; 2024 May; 42(15):1821-1829. PubMed ID: 38412399
[TBL] [Abstract][Full Text] [Related]
13. Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial.
Zhang RX; Wu XJ; Wan DS; Lu ZH; Kong LH; Pan ZZ; Chen G
Ann Oncol; 2012 May; 23(5):1348-1353. PubMed ID: 21940785
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of oral administration of cystine and theanine in patients with colorectal cancer undergoing capecitabine-based adjuvant chemotherapy after surgery: study protocol for a multi-institutional, randomised, double-blinded, placebo-controlled, phase II trial.
Hamaguchi R; Tsuchiya T; Miyata G; Sato T; Takahashi K; Ariyoshi K; Oyamada S; Iwase S
BMJ Open; 2018 Jul; 8(7):e021442. PubMed ID: 30030317
[TBL] [Abstract][Full Text] [Related]
15. Effect of a Novel Soaking Solution Used in Patients With Hand-Foot Syndrome as a Result of Capecitabine Treatment: A Randomized and Self-Controlled Trial.
Xie Y; Wang Q; Hu T; Chen R; Wang J; Chang H; Peng X; Cheng J
Clin Breast Cancer; 2022 Jul; 22(5):e685-e690. PubMed ID: 35354530
[TBL] [Abstract][Full Text] [Related]
16. Topical Silymarin Administration for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized, Double-Blinded, Placebo-Controlled Clinical Trial.
Elyasi S; Shojaee FSR; Allahyari A; Karimi G
Phytother Res; 2017 Sep; 31(9):1323-1329. PubMed ID: 28635153
[TBL] [Abstract][Full Text] [Related]
17. Compliance and effective management of the hand-foot syndrome in colon cancer patients receiving capecitabine as adjuvant chemotherapy.
Son HS; Lee WY; Lee WS; Yun SH; Chun HK
Yonsei Med J; 2009 Dec; 50(6):796-802. PubMed ID: 20046420
[TBL] [Abstract][Full Text] [Related]
18. The Effect of Pyridoxine for Prevention of Hand-Foot Syndrome in Colorectal Cancer Patients with Adjuvant Chemotherapy Using Capecitabine: A Randomized Study.
Ota M; Tatsumi K; Suwa H; Watanabe J; Watanabe K; Osada S; Tanaka K; Shoichi F; Ichikawa Y; Kunisaki C; Endo I
Hepatogastroenterology; 2014 Jun; 61(132):1008-13. PubMed ID: 26158157
[TBL] [Abstract][Full Text] [Related]
19. Possible Pathways of Capecitabine-Induced Hand-Foot Syndrome.
Lou Y; Wang Q; Zheng J; Hu H; Liu L; Hong D; Zeng S
Chem Res Toxicol; 2016 Oct; 29(10):1591-1601. PubMed ID: 27631426
[TBL] [Abstract][Full Text] [Related]
20. Self-identification and management of hand-foot syndrome (HFS): effect of a structured teaching program on patients receiving capecitabine-based chemotherapy for colon cancer.
Murugan K; Ostwal V; Carvalho MD; D'souza A; Achrekar MS; Govindarajan S; Gupta S
Support Care Cancer; 2016 Jun; 24(6):2575-81. PubMed ID: 26715292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
